Stock analysis searches answered, part 23 of 43

Jowell global ltd. bullish and bearish analyst opinions

For “Jowell global ltd. bullish and bearish analyst opinions”, the matching SEC registrant is Jowell Global Ltd., which trades as JWEL and files under Central Index Key 1805594. EDGAR puts it in the “Retail-Nonstore Retailers” industry code with Cayman Islands as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a S-8 POS filed 2026-06-17, across 96 filings on record. This is reference material, not trading advice.

Business description, quoted from the 20-F filed 2026-04-30 by Jowell Global Ltd. (CIK 1805594) — source document:

Jowell Global Ltd. (“Jowell Global” or the “Company”) is an exempted company incorporated in the Cayman Islands with limited liability on August 16, 2019 as a holding company. The Company, through its consolidated variable interest entity (“VIE”), engages primarily in the sale of cosmetic products, nutritional supplements, and household products sourced from third-party manufacturers and distributors, and also offers an online marketplace that enables third-party sellers to sell their products to the Company’s online consumers. A reorganization of the Company’s legal structure (“Reorganization”) was completed on November 1, 2019. The Reorganization involved the incorporation of Jowell Global, a Cayman Islands holding company, Jowell Technology Limited (“Jowell Tech”), a Hong Kong holding company on June 24, 2019, and Shanghai Jowell Technology Co., Ltd. (“Shanghai Jowell”), a new wholly foreign-owned entity (“WFOE”) by Jowell Tech under the laws of the People’s Republic of China (“China” or the “PRC”) on October 15, 2019.

Financial trend for Jowell Global Ltd. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $209.98 million (2022-12-31) to $165.00 million (2025-12-31), a change of -21.4%; net income (loss) went from -$11.54 million (2022-12-31) to -$6.28 million (2025-12-31), a change of +45.6%; total assets went from $71.20 million (2022-12-31) to $21.89 million (2025-12-31), a change of -69.3%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1805594, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Jowell Global Ltd. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Jowell Global Ltd. (CIK 1805594) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-04-30. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 35 8-K or 6-K reports in Jowell Global Ltd.’s recent EDGAR index, the 4 listed here run from 2024-12-19 to 2025-12-30, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1805594 is on the EDGAR company page; the latest 20-F there is dated 2026-04-30 and the oldest filing in the recent index dates from 2020-07-13. Insider trades for Jowell Global Ltd. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Jx luxventure limited bullish and bearish analyst opinions

For “Jx luxventure limited bullish and bearish analyst opinions”, the matching SEC registrant is JX Luxventure Group Inc., which trades as JXG and files under Central Index Key 1546383. EDGAR puts it in the “Wholesale-Durable Goods” industry code with Marshall Islands as its state or country of incorporation; its earlier registered name was JX Luxventure Ltd. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-19, across 251 filings on record. This is reference material, not trading advice.

Business description, quoted from the 20-F filed 2026-05-15 by JX Luxventure Group Inc. (CIK 1546383) — source document:

OPERATING AND FINANCIAL REVIEW AND PROSPECTS 73 A. Operating Results 73 B. Liquidity and Capital Resources 77 C. Research and Development, Patents and Licenses, Etc. 81 D. Trend Information 81 E. Off Balance Sheet Arrangements 81 F. Tabular Disclosure of Contractual Obligations 81 G. Safe Harbor 90 ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES 90 A. Directors and Senior Management 90 B. Compensation 91 C. Board Practices 93 D. Employees 94 E. Share Ownership 95 ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS 96 A. Major Shareholders 96 B. Related Party Transactions 96 C. Interests of Experts and Counsel 97 i Page ITEM 8. FINANCIAL INFORMATION 97 A. Consolidated Statements and Other Financial Information 97 B. Significant Changes 98 ITEM 9.

Financial trend for JX Luxventure Group Inc. from annual reports, periods 2021-12-31 to 2024-12-31: revenue went from $54.04 million (2021-12-31) to $49.84 million (2024-12-31), a change of -7.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1546383, tags Assets, NetIncomeLoss, Revenue; 4 periods shown, dashes mark figures JX Luxventure Group Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on JX Luxventure Group Inc. (CIK 1546383) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-05-15. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 119 8-K or 6-K reports in JX Luxventure Group Inc.’s recent EDGAR index, the 4 listed here run from 2026-04-14 to 2026-09-22, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1546383 is on the EDGAR company page; the latest 20-F there is dated 2026-05-15 and the oldest filing in the recent index dates from 2012-04-04. Insider trades for JX Luxventure Group Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Kairos coffee assembly

What this search refers to. “Kairos coffee assembly” refers to a coffee business or event rather than an issuer; small hospitality firms are recorded only in state or local business registries. Corporate-registry check: OpenCorporates search for “Kairos coffee assembly”.

No SEC filer could be matched to “Kairos coffee assembly” with a single, clear Central Index Key: neither EDGAR’s company index nor its full-text search (phrase “Kairos coffee assembly”) returns a registrant with this name. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “kairos” (search terms considered: kairos, coffee, assembly).

EDGAR’s company index has 89 entities whose registered name contains the word “kairos”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “kairos” 89, “coffee” 294, “assembly” 41. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

Sample EDGAR registrant names, term by term — containing “kairos”: ALPHA KAIROS FUND, LP (CIK 1940753), AYENDA 1, A SERIES OF KAIROS GROWTH, LLC (CIK 1791215), DKMS KAIROS FUND LP (CIK 2097420); containing “coffee”: 151 COFFEE, LLC (CIK 2095665), AMERICAS COFFEE CUP INC (CIK 830746), ANCHOR ISLAND COFFEE LLC (CIK 1999601); containing “assembly”: ALATEC CABLE HARNESS & ASSEMBLY DIVISION INC (CIK 1084159), ARVINMERITOR ASSEMBLY, LLC (CIK 1363714), ASSEMBLY & MANUFACTURING SYSTEMS INC (CIK 98583). These are listed only to show how the individual words map onto unrelated filers; none should be read as the subject of the search.

For this particular search: if “kairos” is a brand or product, the listed parent may file under a different name, so search the parent’s legal name in EDGAR company search. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Katipult technology corp. bullish and bearish analyst opinions

What this search refers to. Katipult Technology Corp. is a Canadian fintech software company that has traded on the TSX Venture Exchange; its filings are on SEDAR+. Official source: www.sedarplus.ca.

No SEC filer could be matched to “Katipult technology corp. bullish and bearish analyst opinions” with a single, clear Central Index Key: the phrase “Katipult technology corp.” appears in 11 EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “katipult” (search terms considered: katipult, technology).

In the 11 most relevant full-text hits returned for “Katipult technology corp.”, filings range from 2018-06-15 to 2024-08-23. The filers whose documents mention it most often are Seed Equity Properties LLC (CIK 0001743305) (9 hits); National Bank Financial Inc. (CIK 0002028017) (1 hit); AURYN RESOURCES INC. (FURY) (CIK 0001514597) (1 hit). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

EDGAR’s company index has 0 entities whose registered name contains the word “katipult”, so the business is most likely not registered with the SEC under that name.

Word by word, the number of EDGAR registrant names containing each term of this search is: “katipult” 0, “technology” 485. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

Sample EDGAR registrant names, term by term — containing “technology”: 100 TECHNOLOGY LLC (CIK 1827627), 102 TECHNOLOGY LLC (CIK 1310921), 128 TECHNOLOGY, INC. (CIK 1627997). These are listed only to show how the individual words map onto unrelated filers; none should be read as the subject of the search.

For this particular search: analyst views on “katipult” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Kenon holdings ltd. bullish and bearish analyst opinions

For “Kenon holdings ltd. bullish and bearish analyst opinions”, the matching SEC registrant is Kenon Holdings Ltd., which trades as KEN and files under Central Index Key 1611005. EDGAR puts it in the “Electric Services” industry code with Singapore as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 6-K filed 2026-09-30, across 479 filings on record. This is reference material, not trading advice.

Business description, quoted from the 20-F filed 2026-03-30 by Kenon Holdings Ltd. (CIK 1611005) — source document:

Operating and Financial Review and Prospects 130 A. Operating Results 145 B. Liquidity and Capital Resources 150 C. Research and Development, Patents and Licenses, Etc. 160 D. Trend Information 161 E. Critical Accounting Estimates 162 F. Disclosure of Registrant’s Action to Recover Erroneously Awarded Compensation 162 ITEM 6. Directors, Senior Management and Employees 163 A. Directors and Senior Management 163 B. Compensation 165 C. Board Practices 166 D. Employees 168 E. Share Ownership 169 ITEM 7. Major Shareholders and Related Party Transactions 170 A. Major Shareholders 170 B. Related Party Transactions 171 C. Interests of Experts and Counsel 171 ITEM 8. Financial Information 171 A. Consolidated Statements and Other Financial Information 171 B. Significant Changes 171 ITEM 9.

Financial trend for Kenon Holdings Ltd. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $573.96 million (2022-12-31) to $871.93 million (2025-12-31), a change of +51.9%; net income (loss) went from $349.66 million (2022-12-31) to $148.26 million (2025-12-31), a change of -57.6%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1611005, tags Assets, ProfitLoss, Revenue; 4 periods shown, dashes mark figures Kenon Holdings Ltd. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Kenon Holdings Ltd. (CIK 1611005) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-03-30. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 363 8-K or 6-K reports in Kenon Holdings Ltd.’s recent EDGAR index, the 4 listed here run from 2026-09-10 to 2026-09-30, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1611005 is on the EDGAR company page; the latest 20-F there is dated 2026-03-30 and the oldest filing in the recent index dates from 2014-06-20. Insider trades for Kenon Holdings Ltd. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Kimball electronics, inc. bullish and bearish analyst opinions

For “Kimball electronics, inc. bullish and bearish analyst opinions”, the matching SEC registrant is Kimball Electronics, Inc., which trades as KE and files under Central Index Key 1606757. EDGAR puts it in the “Printed Circuit Boards” industry code with IN as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a ARS filed 2026-09-30, across 551 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-08-19 by Kimball Electronics, Inc. (CIK 1606757) — source document:

As used herein, the terms “Company,” “Kimball Electronics,” “we,” “us,” or “our” refer to Kimball Electronics, Inc., the Registrant, and its subsidiaries. Reference to a year relates to a fiscal year, ended June 30 of the year indicated, rather than a calendar year unless the context indicates otherwise. Additionally, references to the first, second, third, and fourth quarters refer to those respective quarters of the fiscal year indicated. These are statements made by management, using their best business judgment based upon facts known at the time of the statements or reasonable estimates, about future results, plans, or future performance and business of the Company. Such statements involve risk and uncertainty, and their ultimate validity is affected by a number of factors, both specific and general.

Financial trend for Kimball Electronics, Inc. from annual reports, periods 2023-06-30 to 2026-06-30: revenue went from $1.82 billion (2023-06-30) to $1.43 billion (2026-06-30), a change of -21.5%; net income (loss) went from $55.83 million (2023-06-30) to $27.96 million (2026-06-30), a change of -49.9%; total assets went from $1.26 billion (2023-06-30) to $1.09 billion (2026-06-30), a change of -13.3%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1606757, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures Kimball Electronics, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Kimball Electronics, Inc. (CIK 1606757) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-12, and the most recent 10-K annual report was filed 2026-08-19. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 113 8-K or 6-K reports in Kimball Electronics, Inc.’s recent EDGAR index, the 4 listed here run from 2026-03-19 to 2026-08-12, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1606757 is on the EDGAR company page; the latest 10-K there is dated 2026-08-19 and the oldest filing in the recent index dates from 2014-05-12. Insider trades for Kimball Electronics, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Korro bio, inc. bullish and bearish analyst opinions

For “Korro bio, inc. bullish and bearish analyst opinions”, the matching SEC registrant is Korro Bio, Inc., which trades as KRRO and files under Central Index Key 1703647. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation; its earlier registered name was Frequency Therapeutics, Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-22, across 826 filings on record. This is reference material, not trading advice.

Financial trend for Korro Bio, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $0 (2023-12-31) to $6.39 million (2025-12-31); net income (loss) went from -$58.03 million (2022-12-31) to -$117.26 million (2025-12-31), a change of -102.1%; total assets went from $73.74 million (2022-12-31) to $113.51 million (2025-12-31), a change of +53.9%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1703647, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Korro Bio, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Korro Bio, Inc. (CIK 1703647) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-06, and the most recent 10-K annual report was filed 2026-03-12. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 93 8-K or 6-K reports in Korro Bio, Inc.’s recent EDGAR index, the 4 listed here run from 2026-08-06 to 2026-10-22, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 826 recent EDGAR filings, Korro Bio, Inc. most often filed 4 (297), 144 (166), 8-K (93), 3 (46). A selection from 2026-09-11 to 2026-09-15:

The full record for CIK 1703647 is on the EDGAR company page; the latest 10-K there is dated 2026-03-12 and the oldest filing in the recent index dates from 2017-04-14. Insider trades for Korro Bio, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Lafayette digital acquisition corp. i unit bullish and bearish analyst opinions

For “Lafayette digital acquisition corp. i unit bullish and bearish analyst opinions”, the matching SEC registrant is Lafayette Digital Acquisition Corp. I, which trades as ZKP, ZKPU, ZKPW and files under Central Index Key 2087447. EDGAR puts it in the “Blank Checks” industry code with Cayman Islands as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 10-Q filed 2026-08-13, across 28 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-25 by Lafayette Digital Acquisition Corp. I (CIK 2087447) — source document:

Prior to our sponsor’s initial investment of $25,000, we had no assets, tangible or intangible. On January 12, 2026, we consummated our initial public offering (the “IPO” or “Initial Public Offering”) of 28,750,000 units (the “Units” and, with respect to the Class A ordinary shares included in the Units being offered, the “public shares”), which included the full exercise by the underwriters of their over-allotment option in the amount of 3,750,000 Units, at $10.00 per Unit, generating gross proceeds of $287,500,000. Each Unit consists of one Class A ordinary share and one-fourth of one redeemable warrant (each, a “public warrant”). Each whole public warrant entitles the holder to purchase one Class A ordinary share at a price of $11.50 per share, subject to adjustment.

Financial trend for Lafayette Digital Acquisition Corp. I from quarterly and annual reports (three-month periods), periods 2026-03-31 to 2026-06-30: net income (loss) went from $1.89 million (2026-03-31) to $2.38 million (2026-06-30), a change of +26.4%; total assets went from $290.80 million (2026-03-31) to $293.17 million (2026-06-30), a change of +0.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2087447, tags Assets, NetIncomeLoss; 2 periods shown, dashes mark figures Lafayette Digital Acquisition Corp. I did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Lafayette Digital Acquisition Corp. I (CIK 2087447) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2026-03-25. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Deal and listing documents for Lafayette Digital Acquisition Corp. I — registration statements, prospectuses and merger proxies — are filed on EDGAR; 3 such filings (424B3, S-1, S-1/A) appear in its recent index, the newest dated 2026-01-12.

Current reports. Of the 3 8-K or 6-K reports in Lafayette Digital Acquisition Corp. I’s recent EDGAR index, the 3 listed here run from 2026-01-13 to 2026-01-30, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 2087447 is on the EDGAR company page; the latest 10-K there is dated 2026-03-25 and the oldest filing in the recent index dates from 2025-09-23. Insider trades for Lafayette Digital Acquisition Corp. I appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Landmark optoelectronics corporation bullish and bearish analyst opinions

What this search refers to. Landmark Optoelectronics Corporation is a Taiwanese maker of optical-communication epitaxial wafers listed in Taiwan, which reports through MOPS. Official source: mops.twse.com.tw.

No SEC filer could be matched to “Landmark optoelectronics corporation bullish and bearish analyst opinions” with a single, clear Central Index Key: the phrase “Landmark optoelectronics corporation” appears in 224+ EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “landmark” (search terms considered: landmark, optoelectronics, corporation).

In the 100 most relevant full-text hits returned for “Landmark optoelectronics corporation”, filings range from 2016-07-29 to 2026-10-23. The filers whose documents mention it most often are JNL SERIES TRUST (CIK 0000933691) (32 hits); John Hancock Funds II (CIK 0001331971) (18 hits); JOHN HANCOCK INVESTMENT TRUST (CIK 0000022370) (15 hits); iShares, Inc. (CIK 0000930667) (3 hits). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

EDGAR’s company index has 192+ entities whose registered name contains the word “landmark”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “landmark” 279, “optoelectronics” 10, “corporation” 486. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: analyst views on “landmark” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Lanzatech global, inc. bullish and bearish analyst opinions

For “Lanzatech global, inc. bullish and bearish analyst opinions”, the matching SEC registrant is LanzaTech Global, Inc., which trades as LNZA, LNZAW and files under Central Index Key 1843724. EDGAR puts it in the “Industrial Organic Chemicals” industry code with DE as its state or country of incorporation; its earlier registered name was AMCI Acquisition Corp. II. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-20, across 389 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-31 by LanzaTech Global, Inc. (CIK 1843724) — source document:

Founded in 2005 in New Zealand and now headquartered in Skokie, Illinois, LanzaTech is a leading provider of carbon management and advanced conversion technologies, focused on transforming waste materials into high-value fuels, chemicals, and critical inputs for industry. Our mission is to drive energy resilience, industrial competitiveness, and supply chain security by leveraging robust, scalable biotechnology solutions to maximize the value of domestic resources. Gas fermentation is the centerpiece of our offering. Our proprietary process utilizes abundant, locally-sourced waste streams using existing infrastructure, turning off-gases into valuable commodities, while supporting the strategic objective of maximizing the productivity of industrial assets. The process is conducted on existing industrial land, making efficient use of available space and water resources, and driving productivity from legacy and new assets alike.

Financial trend for LanzaTech Global, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $37.34 million (2022-12-31) to $55.84 million (2025-12-31), a change of +49.5%; net income (loss) went from -$76.36 million (2022-12-31) to -$48.95 million (2025-12-31), a change of +35.9%; total assets went from $176.86 million (2022-12-31) to $100.21 million (2025-12-31), a change of -43.3%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1843724, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures LanzaTech Global, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on LanzaTech Global, Inc. (CIK 1843724) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-14, and the most recent 10-K annual report was filed 2026-03-31. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 88 8-K or 6-K reports in LanzaTech Global, Inc.’s recent EDGAR index, the 4 listed here run from 2026-06-04 to 2026-10-20, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1843724 is on the EDGAR company page; the latest 10-K there is dated 2026-03-31 and the oldest filing in the recent index dates from 2021-02-12. Insider trades for LanzaTech Global, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Lensar inc bullish and bearish analyst opinions

For “Lensar inc bullish and bearish analyst opinions”, the matching SEC registrant is LENSAR, Inc., which trades as LNSR and files under Central Index Key 1320350. EDGAR puts it in the “Surgical & Medical Instruments & Apparatus” industry code with DE as its state or country of incorporation; its earlier registered name was LensAR Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 10-Q filed 2026-08-13, across 327 filings on record. This is reference material, not trading advice.

Financial trend for LENSAR, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $35.36 million (2022-12-31) to $58.44 million (2025-12-31), a change of +65.3%; net income (loss) went from -$19.91 million (2022-12-31) to -$34.28 million (2025-12-31), a change of -72.1%; total assets went from $55.84 million (2022-12-31) to $71.43 million (2025-12-31), a change of +27.9%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1320350, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures LENSAR, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on LENSAR, Inc. (CIK 1320350) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-13, and the most recent 10-K annual report was filed 2026-03-31. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 58 8-K or 6-K reports in LENSAR, Inc.’s recent EDGAR index, the 4 listed here run from 2026-05-08 to 2026-08-13, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 327 recent EDGAR filings, LENSAR, Inc. most often filed 4 (106), 8-K (58), 10-Q (18), SC 13G/A (16). A selection from 2026-06-23 to 2026-08-13:

The full record for CIK 1320350 is on the EDGAR company page; the latest 10-K/A there is dated 2026-04-30 and the oldest filing in the recent index dates from 2005-03-08. Insider trades for LENSAR, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Lifestance health group, inc. bullish and bearish analyst opinions

For “Lifestance health group, inc. bullish and bearish analyst opinions”, the matching SEC registrant is LifeStance Health Group, Inc., which trades as LFST and files under Central Index Key 1845257. EDGAR puts it in the “Services-Health Services” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-16, across 500 filings on record. This is reference material, not trading advice.

Financial trend for LifeStance Health Group, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $859.54 million (2022-12-31) to $1.42 billion (2025-12-31), a change of +65.7%; net income (loss) went from -$215.56 million (2022-12-31) to $9.66 million (2025-12-31), a change of +104.5%; total assets went from $2.17 billion (2022-12-31) to $2.20 billion (2025-12-31), a change of +1.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1845257, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures LifeStance Health Group, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on LifeStance Health Group, Inc. (CIK 1845257) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-06, and the most recent 10-K annual report was filed 2026-02-25. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 46 8-K or 6-K reports in LifeStance Health Group, Inc.’s recent EDGAR index, the 4 listed here run from 2026-07-07 to 2026-10-16, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 500 recent EDGAR filings, LifeStance Health Group, Inc. most often filed 4 (217), 144 (79), 8-K (46), 3 (38). A selection from 2026-09-09 to 2026-10-05:

The full record for CIK 1845257 is on the EDGAR company page; the latest 10-K there is dated 2026-02-25 and the oldest filing in the recent index dates from 2021-02-16. Insider trades for LifeStance Health Group, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Lifezone metals limited bullish and bearish analyst opinions

For “Lifezone metals limited bullish and bearish analyst opinions”, the matching SEC registrant is Lifezone Metals Ltd, which trades as LZM, LZM-WT and files under Central Index Key 1958217. EDGAR puts it in the “Metal Mining” industry code with Isle of Man as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 6-K filed 2026-10-07, across 165 filings on record. This is reference material, not trading advice.

Business description, quoted from the 20-F filed 2026-03-19 by Lifezone Metals Ltd (CIK 1958217) — source document:

Lifezone Metals was incorporated under the laws of the Isle of Man on December 8, 2022. Lifezone Metals' registered office is located at 2nd Floor, St George’s Court, Upper Church Street, Douglas, IM1 1EE, Isle of Man. Our telephone number at that address is +44 (0) 1624 850 500. At Lifezone, we are at the forefront of innovation, championing cleaner and more sustainable metals production to meet global needs. Our primary asset is the Kabanga Nickel Project, which is located in north-west Tanzania. Based on the 2024 Mineral Resource and 2025 Reserve Estimates detailed in the Feasibility Study, we believe Kabanga comprises one of the world’s largest and highest-grade nickel sulfide deposits.

Financial trend for Lifezone Metals Ltd from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $2.93 million (2022-12-31) to $1.06 million (2025-12-31), a change of -63.9%; net income (loss) went from -$25.49 million (2022-12-31) to -$14.11 million (2025-12-31), a change of +44.7%; total assets went from $96.98 million (2022-12-31) to $175.75 million (2025-12-31), a change of +81.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1958217, tags Assets, ProfitLoss, Revenue; 4 periods shown, dashes mark figures Lifezone Metals Ltd did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Lifezone Metals Ltd (CIK 1958217) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-03-19. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 40 8-K or 6-K reports in Lifezone Metals Ltd’s recent EDGAR index, the 4 listed here run from 2026-07-09 to 2026-10-07, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1958217 is on the EDGAR company page; the latest 20-F there is dated 2026-03-19 and the oldest filing in the recent index dates from 2023-01-03. Insider trades for Lifezone Metals Ltd appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Limoneira company bullish and bearish analyst opinions

For “Limoneira company bullish and bearish analyst opinions”, the matching SEC registrant is Limoneira CO, which trades as LMNR and files under Central Index Key 1342423. EDGAR puts it in the “Agricultural Production-Crops” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-22, across 918 filings on record. This is reference material, not trading advice.

Further, any references to our website are intended to be interactive textual references only. Overview We are primarily an agribusiness company founded and based in Santa Paula, California, committed to responsibly using and managing our approximately 10,500 acres of land, water resources and other assets to maximize long-term stockholder value. Our operations consist of fruit production, sales and marketing, rental operations, real estate and capital investment activities. Agribusiness activities are performed through these four reporting segments: We are one of California’s oldest citrus growers and according to the California Avocado Commission, we are one of the largest growers of avocados in the United States. In addition to growing lemons and avocados, we grow oranges and wine grapes.

Analyst ratings, price targets and “bullish” or “bearish” calls on Limoneira CO (CIK 1342423) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-09-09, and the most recent 10-K annual report was filed 2025-12-23. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Updated Oct 25, 2026 ET

Liqtech international, inc. bullish and bearish analyst opinions

For “Liqtech international, inc. bullish and bearish analyst opinions”, the matching SEC registrant is LIQTECH INTERNATIONAL INC, which trades as LIQT and files under Central Index Key 1307579. EDGAR puts it in the “Misc Industrial & Commercial Machinery & Equipment” industry code with NV as its state or country of incorporation; its earlier registered name was Blue Moose Media Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a DEFA14A filed 2026-10-23, across 509 filings on record. This is reference material, not trading advice.

Financial trend for LIQTECH INTERNATIONAL INC from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $15.98 million (2022-12-31) to $16.51 million (2025-12-31), a change of +3.3%; net income (loss) went from -$14.17 million (2022-12-31) to -$8.53 million (2025-12-31), a change of +39.8%; total assets went from $40.13 million (2022-12-31) to $27.28 million (2025-12-31), a change of -32.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1307579, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerIncludingAssessedTax; 4 periods shown, dashes mark figures LIQTECH INTERNATIONAL INC did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on LIQTECH INTERNATIONAL INC (CIK 1307579) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2019-03-28, and the most recent 10-K annual report was filed 2026-02-27. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 76 8-K or 6-K reports in LIQTECH INTERNATIONAL INC’s recent EDGAR index, the 4 listed here run from 2026-06-09 to 2026-10-06, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1307579 is on the EDGAR company page; the latest 10-K/A there is dated 2026-03-19 and the oldest filing in the recent index dates from 2004-10-29. Insider trades for LIQTECH INTERNATIONAL INC appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Lqr house inc. bullish and bearish analyst opinions

For “Lqr house inc. bullish and bearish analyst opinions”, the matching SEC registrant is LQR House Inc., which trades as YHC and files under Central Index Key 1843165. EDGAR puts it in the “Beverages” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-23, across 233 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-04-15 by LQR House Inc. (CIK 1843165) — source document:

This platform delivers a diverse range of spirits, wines, and champagnes from esteemed retail partners like Country Wine & Spirits. Beyond its role in the e-commerce sector, LQR is a marketing agency with a specialized focus on the alcohol industry. We also intend to integrate the supply, sales, and marketing facets of the alcoholic beverage space into one easy to use platform and become the one-stop-shop for everything related to alcohol. To date, our core business includes e-commerce sales in the United States through CWSpirits.com, growing our in-house tequila brand SWOL Tequila, and developing marketing strategies for external brands. These strategies include banner ads on our site, targeted email campaigns, and influencer marketing, all designed to drive product awareness and sales.

Financial trend for LQR House Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $601,131 (2022-12-31) to $1.12 million (2023-12-31), a change of +86.4%; net income (loss) went from -$1.84 million (2022-12-31) to -$25.52 million (2025-12-31), a change of -1285.5%; total assets went from $2.63 million (2022-12-31) to $31.23 million (2025-12-31), a change of +1087.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1843165, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures LQR House Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on LQR House Inc. (CIK 1843165) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2026-04-15. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 50 8-K or 6-K reports in LQR House Inc.’s recent EDGAR index, the 4 listed here run from 2026-07-15 to 2026-10-23, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1843165 is on the EDGAR company page; the latest 10-K there is dated 2026-04-15 and the oldest filing in the recent index dates from 2021-01-29. Insider trades for LQR House Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Lument finance trust, inc. bullish and bearish analyst opinions

For “Lument finance trust, inc. bullish and bearish analyst opinions”, the matching SEC registrant is Lument Finance Trust, Inc., which trades as LFT, LFT-PA and files under Central Index Key 1547546. EDGAR puts it in the “Real Estate Investment Trusts” industry code with MD as its state or country of incorporation; its earlier registered name was Lument Finance Trust, Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-06, across 634 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-23 by Lument Finance Trust, Inc. (CIK 1547546) — source document:

References herein to "Lument Finance Trust," "Company," "LFT," "we," "us," or "our" refer to Lument Finance Trust, Inc., a Maryland corporation, and its subsidiaries unless the context specifically requires otherwise. Our Company We are a REIT focused on investing in, originating, financing and managing a portfolio of commercial real estate ("CRE") debt investments. We primarily invest in or originate transitional floating rate CRE mortgage loans with an emphasis on middle-market multifamily assets. We may also invest in other CRE-related investments including mezzanine loans, preferred equity, commercial mortgage-backed securities ("CMBS"), fixed rate loans, construction loans and other CRE debt instruments. We are externally managed by our manager, Lument Investment Management, LLC (the "Manager" or "Lument IM") pursuant to the terms of our Management Agreement (the "Management Agreement").

Financial trend for Lument Finance Trust, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from $9.86 million (2022-12-31) to -$2.75 million (2025-12-31), a change of -127.8%; total assets went from $1.13 billion (2022-12-31) to $1.22 billion (2025-12-31), a change of +7.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1547546, tags Assets, NetIncomeLoss; 4 periods shown, dashes mark figures Lument Finance Trust, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Lument Finance Trust, Inc. (CIK 1547546) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-13, and the most recent 10-K annual report was filed 2026-03-23. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 177 8-K or 6-K reports in Lument Finance Trust, Inc.’s recent EDGAR index, the 4 listed here run from 2026-07-30 to 2026-10-06, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1547546 is on the EDGAR company page; the latest 10-K there is dated 2026-03-23 and the oldest filing in the recent index dates from 2012-05-23. Insider trades for Lument Finance Trust, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Luxexperience b.v. bullish and bearish analyst opinions

For “Luxexperience b.v. bullish and bearish analyst opinions”, the matching SEC registrant is LuxExperience B.V., which trades as LUXE and files under Central Index Key 1831907. EDGAR puts it in the “Retail-Catalog & Mail-Order Houses” industry code with Netherlands as its state or country of incorporation; its earlier registered name was MYT Netherlands Parent B.V.. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-15, across 136 filings on record. This is reference material, not trading advice.

Business description, quoted from the 20-F filed 2026-09-16 by LuxExperience B.V. (CIK 1831907) — source document:

Directors, Senior Management and Employees ​ 80 Item 7: Major shareholders and related party transactions ​ 98 Item 8. Financial Information ​ 101 Item 9. The Offer and Listing ​ 102 Item 10. Additional Information ​ 102 Item 11. Quantitative and qualitative Disclosures about Market Risk ​ 122 Item 12. Description of Securities Other than Equity Securities ​ 122 Item 13. Defaults, Dividend Arrearages and Delinquencies ​ 123 Item 14. Material Modifications to the Rights of Security Holders and Use of Proceeds ​ 123 Item 15. Controls and Procedures ​ 123 Item 16A. Audit Committee Financial Expert ​ 124 Item 16B. Code of Ethics ​ 124 Item 16C. Principal Accountant Fees and Services ​ 125 Item 16D. Exemptions from the Listing Standards for Audit Committees ​ 125 Item 16E. Purchases of Equity Securities by the Issuer and Affiliated Purchasers ​ 125 Item 16F. Change in Registrant’s Certifying Accountant ​ 125 Item 16G. Corporate Governance ​ 125 Item 16H. Mine Safety Disclosure ​ 128 Item 16I. Disclosure regarding foreign jurisdictions that prevent inspections ​ 128 Item 16J. Insider trading policies ​ 128 Item 16K.

Financial trend for LuxExperience B.V. from annual reports, periods 2022-06-30 to 2025-06-30: revenue went from 687,781,000 EUR (2022-06-30) to 1,262,277,000 EUR (2025-06-30), a change of +83.5%; net income (loss) went from -9,317,000 EUR (2022-06-30) to 569,959,000 EUR (2025-06-30), a change of +6217.4%; total assets went from 614,776,000 EUR (2022-06-30) to 2,281,897,000 EUR (2025-06-30), a change of +271.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1831907, tags Assets, ProfitLoss, Revenue; 4 periods shown, dashes mark figures LuxExperience B.V. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on LuxExperience B.V. (CIK 1831907) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-09-16. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 50 8-K or 6-K reports in LuxExperience B.V.’s recent EDGAR index, the 4 listed here run from 2026-04-30 to 2026-09-25, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1831907 is on the EDGAR company page; the latest 20-F there is dated 2026-09-16 and the oldest filing in the recent index dates from 2020-11-23. Insider trades for LuxExperience B.V. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Luxfer holdings plc bullish and bearish analyst opinions

For “Luxfer holdings plc bullish and bearish analyst opinions”, the matching SEC registrant is LUXFER HOLDINGS PLC, which trades as LXFR and files under Central Index Key 1096056. EDGAR puts it in the “Industrial Inorganic Chemicals” industry code with United Kingdom as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a DEFA14A filed 2026-10-16, across 706 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-02-24 by LUXFER HOLDINGS PLC (CIK 1096056) — source document:

We develop and manufacture high-performance materials, components, and high-pressure gas containment solutions for customers operating in defense, first response and healthcare, transportation, and specialty industrial markets. Luxfer’s strategy is centered on value creation through the application of deep technical expertise, proprietary technologies, and close collaboration with customers to solve complex engineering challenges. Our core product lines include magnesium alloys and powders, zirconium-based chemicals, aluminum and composite high-pressure gas cylinders, and carbon composite technologies. We believe we hold leading positions in several of our principal markets, including magnesium alloys and powders for aerospace, defense, and commercial applications; zirconium chemicals used in automotive catalytic converters and industrial catalysis; and high-pressure composite cylinders used in self-contained breathing apparatus and in the transport and storage of compressed natural gas (“CNG”) and hydrogen.

Financial trend for LUXFER HOLDINGS PLC from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $423.40 million (2022-12-31) to $384.60 million (2025-12-31), a change of -9.2%; net income (loss) went from $26.90 million (2022-12-31) to $7.70 million (2025-12-31), a change of -71.4%; total assets went from $407.10 million (2022-12-31) to $369.70 million (2025-12-31), a change of -9.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1096056, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures LUXFER HOLDINGS PLC did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on LUXFER HOLDINGS PLC (CIK 1096056) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2024-07-30, and the most recent 10-K annual report was filed 2026-02-24. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 184 8-K or 6-K reports in LUXFER HOLDINGS PLC’s recent EDGAR index, the 4 listed here run from 2026-07-23 to 2026-09-09, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1096056 is on the EDGAR company page; the latest 10-K there is dated 2026-02-24 and the oldest filing in the recent index dates from 2002-04-11. Insider trades for LUXFER HOLDINGS PLC appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Macrogenics, inc. bullish and bearish analyst opinions

For “Macrogenics, inc. bullish and bearish analyst opinions”, the matching SEC registrant is MACROGENICS INC, which trades as MGNX and files under Central Index Key 1125345. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-23, across 939 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-09 by MACROGENICS INC (CIK 1125345) — source document:

Except as otherwise indicated herein or as the context otherwise requires, references in this annual report on Form 10-K to "MacroGenics," the "company," "we," "us" and "our" refer to MacroGenics, Inc. and its consolidated subsidiaries. “MacroGenics ® , the MacroGenics logo, DART ® , TRIDENT ® and the phrases Breakthrough Biologics, Life-Changing Medicines ® and Developing Breakthrough Biologics, Life-Changing Medicines ® are our trademarks. The other trademarks, trade names and service marks appearing in this report are the property of their respective owners. Overview We are a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer. We generate our pipeline of product candidates from our proprietary suite of antibody technology platforms.

Financial trend for MACROGENICS INC from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $151.94 million (2022-12-31) to $149.50 million (2025-12-31), a change of -1.6%; net income (loss) went from -$119.76 million (2022-12-31) to -$74.62 million (2025-12-31), a change of +37.7%; total assets went from $280.47 million (2022-12-31) to $256.85 million (2025-12-31), a change of -8.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1125345, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures MACROGENICS INC did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on MACROGENICS INC (CIK 1125345) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-13, and the most recent 10-K annual report was filed 2026-03-09. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 147 8-K or 6-K reports in MACROGENICS INC’s recent EDGAR index, the 4 listed here run from 2026-07-08 to 2026-10-23, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1125345 is on the EDGAR company page; the latest 10-K there is dated 2026-03-09 and the oldest filing in the recent index dates from 2003-11-12. Insider trades for MACROGENICS INC appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Magnum mining and exploration limited bullish and bearish analyst opinions

Read from its name, “Magnum mining and exploration limited” is a a Commonwealth jurisdiction (most often Hong Kong, Australia, Singapore or Canada) entity — “Limited” is the company form used across Hong Kong, Australia, Singapore and other Commonwealth markets. Its accounts and exchange notices are published through that market’s exchange filing system (HKEXnews, ASX announcements, SGXNet or SEDAR+) (www.hkexnews.hk); the SEC only receives filings from such a company if it sells registered securities in the U.S.

No SEC filer could be matched to “Magnum mining and exploration limited bullish and bearish analyst opinions” with a single, clear Central Index Key: neither EDGAR’s company index nor its full-text search (phrase “Magnum mining and exploration limited”) returns a registrant with this name. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “magnum” (search terms considered: magnum, mining, exploration).

Even the shorter phrase “Magnum mining exploration” returns no EDGAR full-text hits, so no SEC filing since 2001 mentions it; the terms in this search (magnum, mining, exploration) point to a business outside the SEC system or one known by another legal name.

EDGAR’s company index has 66 entities whose registered name contains the word “magnum”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “magnum” 66, “mining” 474, “exploration” 483. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

Sample EDGAR registrant names, term by term — containing “magnum”: 3RC/MAGNUM HOLDINGS LLC (CIK 1966000), 3RC/MAGNUM INVESCO LLC (CIK 1965997), ADVANCED EQUITIES MAGNUM INVESTMENTS I LLC (CIK 1439783); containing “mining”: 17 WEST MINING (CIK 1078454), 360 MINING, INC. (CIK 1958182), 3C MINING GOLD CORP (CIK 1971015); containing “exploration”: 2022 SPACE EXPLORATION FUND LLC (CIK 1931110), ABACUS MINING & EXPLORATION CORP (CIK 1284237), ACERO-MARTIN EXPLORATION INC (CIK 1344287). These are listed only to show how the individual words map onto unrelated filers; none should be read as the subject of the search.

For this particular search: analyst views on “magnum” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Maplight therapeutics, inc. bullish and bearish analyst opinions

For “Maplight therapeutics, inc. bullish and bearish analyst opinions”, the matching SEC registrant is MapLight Therapeutics, Inc., which trades as MPLT and files under Central Index Key 1770069. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation; its earlier registered name was Alvarado Therapeutics, Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-16, across 209 filings on record. This is reference material, not trading advice.

Financial trend for MapLight Therapeutics, Inc. from annual reports, periods 2024-12-31 to 2025-12-31: net income (loss) went from -$77.58 million (2024-12-31) to -$161.15 million (2025-12-31), a change of -107.7%; total assets went from $136.92 million (2024-12-31) to $479.51 million (2025-12-31), a change of +250.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1770069, tags Assets, NetIncomeLoss; 2 periods shown, dashes mark figures MapLight Therapeutics, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on MapLight Therapeutics, Inc. (CIK 1770069) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-13, and the most recent 10-K annual report was filed 2026-03-26. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 11 8-K or 6-K reports in MapLight Therapeutics, Inc.’s recent EDGAR index, the 4 listed here run from 2026-06-22 to 2026-08-13, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 209 recent EDGAR filings, MapLight Therapeutics, Inc. most often filed 4 (82), 144 (45), 3 (17), 8-K (11). A selection from 2026-10-16 to 2026-10-16:

The full record for CIK 1770069 is on the EDGAR company page; the latest 10-K there is dated 2026-03-26 and the oldest filing in the recent index dates from 2019-03-08. Insider trades for MapLight Therapeutics, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Mbia inc. bullish and bearish analyst opinions

For “Mbia inc. bullish and bearish analyst opinions”, the matching SEC registrant is MBIA INC, which trades as MBI and files under Central Index Key 814585. EDGAR puts it in the “Surety Insurance” industry code with CT as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a SCHEDULE 13G filed 2026-08-14, across 1000 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-02-26 by MBIA INC (CIK 814585) — source document:

As used in this Annual Report on Form 10-K, (i) “MBIA,” the “Company,” “we,” “our” and “us” refer to MBIA Inc., a Connecticut corporation incorporated in 1986, together with its subsidiaries, and (ii) unless otherwise indicated or the context otherwise requires, references to “MBIA Corp.” are to MBIA Insurance Corporation together with MBIA Mexico S.A. de C.V. (“MBIA Mexico”). OVERVIEW The Company’s operating subsidiaries are running off their insured portfolios. Today, the Company’s primary objectives are ensuring that adequate liquidity exists at the holding company to satisfy all of its outstanding obligations, mitigating losses at National Public Finance Guarantee Corporation (“National”) and MBIA Corp., and maximizing recoveries on paid insurance claims.

Financial trend for MBIA INC from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $154.00 million (2022-12-31) to $80.00 million (2025-12-31), a change of -48.1%; net income (loss) went from -$195.00 million (2022-12-31) to -$177.00 million (2025-12-31), a change of +9.2%; total assets went from $3.38 billion (2022-12-31) to $2.01 billion (2025-12-31), a change of -40.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 814585, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures MBIA INC did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on MBIA INC (CIK 814585) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-06, and the most recent 10-K annual report was filed 2026-02-26. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 158 8-K or 6-K reports in MBIA INC’s recent EDGAR index, the 4 listed here run from 2025-11-04 to 2026-08-06, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 814585 is on the EDGAR company page; the latest 10-K there is dated 2026-02-26 and the oldest filing in the recent index dates from 2010-08-10. Insider trades for MBIA INC appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Mdxhealth s.a. bullish and bearish analyst opinions

For “Mdxhealth s.a. bullish and bearish analyst opinions”, the matching SEC registrant is MDxHealth SA, which trades as MDXH and files under Central Index Key 1872529. EDGAR puts it in the “Services-Medical Laboratories” industry code with Belgium as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 6-K filed 2026-10-16, across 182 filings on record. This is reference material, not trading advice.

Business description, quoted from the 20-F filed 2026-04-03 by MDxHealth SA (CIK 1872529) — source document:

We were incorporated on January 10, 2003 as a company with limited liability ( naamloze vennootschap/société anonyme ) incorporated and operating under the laws of Belgium. We are registered with the legal entities register (Liège) under enterprise number 0479.292.440. We were publicly listed on Euronext Brussels in June 2006 and we had ADSs listed on the Nasdaq Capital Market in November 2021. In November 2023, we completed a share consolidation of our ordinary shares by means of a 1-for-10 reverse split, such that following the share consolidation each ADS represented one ordinary share (instead of 10 ordinary shares previously). Following the share consolidation and also during November 2023, we completed the mandatory exchange of all of our ADSs for one ordinary share each and subsequently terminated our ADS facility.

Financial trend for MDxHealth SA from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $37.05 million (2022-12-31) to $107.88 million (2025-12-31), a change of +191.1%; net income (loss) went from -$44.04 million (2022-12-31) to -$33.52 million (2025-12-31), a change of +23.9%; total assets went from $119.14 million (2022-12-31) to $147.95 million (2025-12-31), a change of +24.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1872529, tags Assets, ProfitLoss, Revenue; 4 periods shown, dashes mark figures MDxHealth SA did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on MDxHealth SA (CIK 1872529) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-04-03. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 82 8-K or 6-K reports in MDxHealth SA’s recent EDGAR index, the 4 listed here run from 2026-08-13 to 2026-10-16, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1872529 is on the EDGAR company page; the latest 20-F there is dated 2026-04-03 and the oldest filing in the recent index dates from 2021-08-09. Insider trades for MDxHealth SA appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Melco resorts & entertainment limited bullish and bearish analyst opinions

For “Melco resorts & entertainment limited bullish and bearish analyst opinions”, the matching SEC registrant is Melco Resorts & Entertainment LTD, which trades as MLCO and files under Central Index Key 1381640. EDGAR puts it in the “Hotels & Motels” industry code with Cayman Islands as its state or country of incorporation; its earlier registered name was Melco Crown Entertainment LTD. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 6-K filed 2026-10-23, across 760 filings on record. This is reference material, not trading advice.

Business description, quoted from the 20-F filed 2026-03-13 by Melco Resorts & Entertainment LTD (CIK 1381640) — source document:

OPERATING AND FINANCIAL REVIEW AND PROSPECTS 127 A. OPERATING RESULTS 127 B. LIQUIDITY AND CAPITAL RESOURCES 140 C. RESEARCH AND DEVELOPMENT, PATENTS AND LICENSES, ETC. 147 D. TREND INFORMATION 148 E. CRITICAL ACCOUNTING ESTIMATES 149 ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES 153 A. DIRECTORS AND SENIOR MANAGEMENT 153 B. COMPENSATION OF DIRECTORS AND EXECUTIVE OFFICERS 158 C. BOARD PRACTICES 158 D. EMPLOYEES 164 E. SHARE OWNERSHIP 165 F. DISCLOSURE OF A REGISTRANT’S ACTION TO RECOVER ERRONEOUSLY AWARDED COMPENSATION 170 ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS 170 A. MAJOR SHAREHOLDERS 170 B. RELATED PARTY TRANSACTIONS 171 C. INTERESTS OF EXPERTS AND COUNSEL 172 ITEM 8. FINANCIAL INFORMATION 172 A. CONSOLIDATED STATEMENTS AND OTHER FINANCIAL INFORMATION 172 B. SIGNIFICANT CHANGES 173 ITEM 9.

Financial trend for Melco Resorts & Entertainment LTD from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $1.35 billion (2022-12-31) to $5.16 billion (2025-12-31), a change of +282.5%; net income (loss) went from -$930.53 million (2022-12-31) to $185.04 million (2025-12-31), a change of +119.9%; total assets went from $9.30 billion (2022-12-31) to $7.60 billion (2025-12-31), a change of -18.3%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1381640, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Melco Resorts & Entertainment LTD did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Melco Resorts & Entertainment LTD (CIK 1381640) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-03-13. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 534 8-K or 6-K reports in Melco Resorts & Entertainment LTD’s recent EDGAR index, the 4 listed here run from 2026-08-24 to 2026-10-23, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1381640 is on the EDGAR company page; the latest 20-F there is dated 2026-03-13 and the oldest filing in the recent index dates from 2006-12-01. Insider trades for Melco Resorts & Entertainment LTD appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Mh robot & automation co., ltd. bullish and bearish analyst opinions

The legal-form ending in “Mh robot & automation co., ltd.” is the clue: “Co., Ltd.” is the English rendering used by limited companies across East Asia. A company of that kind reports in China, Taiwan, Korea or Japan, so the place to read its annual report and announcements is the home-exchange disclosure system (SSE/SZSE in mainland China, MOPS in Taiwan, DART in Korea, EDINET in Japan) — mops.twse.com.tw.

No SEC filer could be matched to “Mh robot & automation co., ltd. bullish and bearish analyst opinions” with a single, clear Central Index Key: neither EDGAR’s company index nor its full-text search (phrase “Mh robot & automation co., ltd.”) returns a registrant with this name. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “robot” (search terms considered: robot, automation).

Even the shorter phrase “Mh robot automation” returns no EDGAR full-text hits, so no SEC filing since 2001 mentions it; the terms in this search (robot, automation) point to a business outside the SEC system or one known by another legal name.

EDGAR’s company index has 32 entities whose registered name contains the word “robot”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “robot” 32, “automation” 162. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

Sample EDGAR registrant names, term by term — containing “robot”: BHS ROBOT FUND I, LLC (CIK 2150049), COMPLETE ROBOT INC. (CIK 2138445), ELEMENT ROBOT LLC (CIK 1608727); containing “automation”: AI AUTOMATION CATENA BBVC, A SERIES OF A MASTER SERIES, LLC (CIK 2143808), ALLOY AUTOMATION INC (CIK 1922351), ANALOG DESIGN AUTOMATION INC (CIK 1129583). These are listed only to show how the individual words map onto unrelated filers; none should be read as the subject of the search.

For this particular search: analyst views on “robot” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Microalgo inc. bullish and bearish analyst opinions

For “Microalgo inc. bullish and bearish analyst opinions”, the matching SEC registrant is MicroAlgo Inc., which trades as MLGO, VENAF and files under Central Index Key 1800392. EDGAR puts it in the “Services-Computer Programming Services” industry code with Cayman Islands as its state or country of incorporation; its earlier registered name was Venus Acquisition Corp. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 6-K filed 2026-08-28, across 197 filings on record. This is reference material, not trading advice.

Business description, quoted from the 20-F filed 2026-04-01 by MicroAlgo Inc. (CIK 1800392) — source document:

AND DEVELOPMENT OF OUR COMPANY Corporate History MicroAlgo Inc. (“MicroAlgo” or the “Company”) (f/k/a Venus Acquisition Corporation (“Venus”)), a Cayman Islands exempted company incorporated on May 14, 2018, entered into the Merger Agreement dated June 10, 2021 (as amended on January 24, 2022, August 2, 2022, August 3, 2022 and August 10, 2022, the “Merger Agreement”), by and among WiMi Hologram Cloud Inc. (“WiMi” or the “Majority Shareholder”), Venus, Venus Merger Sub Corporation (“Venus Merger Sub”), a Cayman Islands exempted company incorporated for the purpose of effectuating the Business Combination, and VIYI Algorithm Inc. (“VIYI”), a Cayman Islands exempted company. On December 9, 2022, in accordance with the Merger Agreement, the closing of the business combination (the “Closing”) occurred.

Financial trend for MicroAlgo Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $87.13 million (2022-12-31) to $60.05 million (2025-12-31), a change of -31.1%; net income (loss) went from -$6.96 million (2022-12-31) to $18.15 million (2025-12-31), a change of +360.6%; total assets went from $72.09 million (2022-12-31) to $350.35 million (2025-12-31), a change of +386.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1800392, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures MicroAlgo Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on MicroAlgo Inc. (CIK 1800392) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2023-03-29, and the most recent 20-F annual report was filed 2026-04-01. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 47 8-K or 6-K reports in MicroAlgo Inc.’s recent EDGAR index, the 4 listed here run from 2025-10-10 to 2026-08-28, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1800392 is on the EDGAR company page; the latest 20-F there is dated 2026-04-01 and the oldest filing in the recent index dates from 2020-01-22. Insider trades for MicroAlgo Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Mink therapeutics, inc. bullish and bearish analyst opinions

For “Mink therapeutics, inc. bullish and bearish analyst opinions”, the matching SEC registrant is MiNK Therapeutics, Inc., which trades as INKT and files under Central Index Key 1840229. EDGAR puts it in the “Biological Products, (No Diagnostic Substances)” industry code with DE as its state or country of incorporation; its earlier registered name was AgenTus Therapeutics, Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-14, across 265 filings on record. This is reference material, not trading advice.

Financial trend for MiNK Therapeutics, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -$27.99 million (2022-12-31) to -$12.49 million (2025-12-31), a change of +55.4%; total assets went from $21.47 million (2022-12-31) to $14.24 million (2025-12-31), a change of -33.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1840229, tags Assets, NetIncomeLoss; 4 periods shown, dashes mark figures MiNK Therapeutics, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on MiNK Therapeutics, Inc. (CIK 1840229) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-13, and the most recent 10-K annual report was filed 2026-03-31. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 42 8-K or 6-K reports in MiNK Therapeutics, Inc.’s recent EDGAR index, the 4 listed here run from 2026-03-31 to 2026-08-13, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 265 recent EDGAR filings, MiNK Therapeutics, Inc. most often filed 4 (125), 8-K (42), 10-Q (15), 3 (14). A selection from 2026-09-02 to 2026-10-14:

The full record for CIK 1840229 is on the EDGAR company page; the latest 10-K there is dated 2026-03-31 and the oldest filing in the recent index dates from 2021-01-22. Insider trades for MiNK Therapeutics, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Mobia medical, inc. common stock bullish and bearish analyst opinions

For “Mobia medical, inc. common stock bullish and bearish analyst opinions”, the matching SEC registrant is Mobia Medical, Inc., which trades as MOBI and files under Central Index Key 1489993. EDGAR puts it in the “Surgical & Medical Instruments & Apparatus” industry code with DE as its state or country of incorporation; its earlier registered name was MicroTransponder, Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K/A filed 2026-10-16, across 82 filings on record. This is reference material, not trading advice.

Financial trend for Mobia Medical, Inc. from quarterly and annual reports (three-month periods), periods 2025-06-30 to 2026-06-30: revenue went from $6.67 million (2025-06-30) to $13.51 million (2026-06-30), a change of +102.4%; net income (loss) went from -$10.49 million (2025-06-30) to -$21.04 million (2026-06-30), a change of -100.6%; total assets went from $73.60 million (2026-03-31) to $195.28 million (2026-06-30), a change of +165.3%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1489993, tags Assets, NetIncomeLoss, Revenues; 3 periods shown, dashes mark figures Mobia Medical, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Mobia Medical, Inc. (CIK 1489993) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-11. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 4 8-K or 6-K reports in Mobia Medical, Inc.’s recent EDGAR index, the 4 listed here run from 2026-05-11 to 2026-08-11, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 82 recent EDGAR filings, Mobia Medical, Inc. most often filed 4 (25), 3 (19), D (12), SCHEDULE 13G (4). A selection from 2026-08-20 to 2026-10-16:

The full record for CIK 1489993 is on the EDGAR company page and the oldest filing in the recent index dates from 2010-04-23. Insider trades for Mobia Medical, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Mountain crest acquisition 6 corp. bullish and bearish analyst opinions

For “Mountain crest acquisition 6 corp. bullish and bearish analyst opinions”, the matching SEC registrant is Mountain Crest Acquisition 6 Corp., which trades as MCAH, MCAHR, MCAHU and files under Central Index Key 2109876. EDGAR puts it in the “Blank Checks” industry code with Virgin Islands, British as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 10-Q filed 2026-08-14, across 26 filings on record. This is reference material, not trading advice.

Financial trend for Mountain Crest Acquisition 6 Corp. from quarterly and annual reports (three-month periods), periods 2026-03-31 to 2026-06-30: net income (loss) went from -$43,470 (2026-03-31) to $348,644 (2026-06-30), a change of +902.0%; total assets went from $116,950 (2026-03-31) to $60.42 million (2026-06-30), a change of +51559.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2109876, tags Assets, NetIncomeLoss; 2 periods shown, dashes mark figures Mountain Crest Acquisition 6 Corp. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Mountain Crest Acquisition 6 Corp. (CIK 2109876) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Deal and listing documents for Mountain Crest Acquisition 6 Corp. — registration statements, prospectuses and merger proxies — are filed on EDGAR; 2 such filings (424B4, S-1) appear in its recent index, the newest dated 2026-04-30.

Current reports. Of the 3 8-K or 6-K reports in Mountain Crest Acquisition 6 Corp.’s recent EDGAR index, the 3 listed here run from 2026-05-05 to 2026-06-17, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 26 recent EDGAR filings, Mountain Crest Acquisition 6 Corp. most often filed SCHEDULE 13G (5), 3 (5), 4 (4), 8-K (3). A selection from 2026-08-12 to 2026-08-14:

The full record for CIK 2109876 is on the EDGAR company page and the oldest filing in the recent index dates from 2026-02-06. Insider trades for Mountain Crest Acquisition 6 Corp. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Mozayyx acquisition corp. bullish and bearish analyst opinions

For “Mozayyx acquisition corp. bullish and bearish analyst opinions”, the matching SEC registrant is MOZAYYX Acquisition Corp., which trades as MZYX, MZYX-UN, MZYX-WT and files under Central Index Key 2097376. EDGAR puts it in the “Blank Checks” industry code with Cayman Islands as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 3 filed 2026-09-08, across 36 filings on record. This is reference material, not trading advice.

Financial trend for MOZAYYX Acquisition Corp. from quarterly and annual reports (three-month periods), periods 2026-03-31 to 2026-06-30: net income (loss) went from $822,679 (2026-03-31) to $2.53 million (2026-06-30), a change of +208.0%; total assets went from $302.49 million (2026-03-31) to $305.03 million (2026-06-30), a change of +0.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 2097376, tags Assets, NetIncomeLoss; 2 periods shown, dashes mark figures MOZAYYX Acquisition Corp. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on MOZAYYX Acquisition Corp. (CIK 2097376) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Deal and listing documents for MOZAYYX Acquisition Corp. — registration statements, prospectuses and merger proxies — are filed on EDGAR; 7 such filings (424B3, 424B4, S-1, S-1/A, S-1MEF) appear in its recent index, the newest dated 2026-02-26.

Current reports. Of the 4 8-K or 6-K reports in MOZAYYX Acquisition Corp.’s recent EDGAR index, the 4 listed here run from 2026-02-27 to 2026-06-01, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 36 recent EDGAR filings, MOZAYYX Acquisition Corp. most often filed 3 (8), 8-K (4), SCHEDULE 13G (4), 10-Q (2). A selection from 2026-06-24 to 2026-09-08:

The full record for CIK 2097376 is on the EDGAR company page and the oldest filing in the recent index dates from 2025-11-19. Insider trades for MOZAYYX Acquisition Corp. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Mustang bio, inc. bullish and bearish analyst opinions

For “Mustang bio, inc. bullish and bearish analyst opinions”, the matching SEC registrant is MUSTANG BIO, INC., which trades as MBIO and files under Central Index Key 1680048. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-15, across 403 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-19 by MUSTANG BIO, INC. (CIK 1680048) — source document:

We aim to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development and eventually either out-licensing or bringing the technologies to market. Our pipeline is currently focused on novel therapies for solid tumors. For these therapies we have partnered with world class research institutions, including the City of Hope National Medical Center (“COH” or “City of Hope”), and Nationwide Children’s Hospital (“Nationwide”). Development Pipeline Our pipeline is being developed under exclusive licenses from two world class research institutions. Our strategy is to license these technologies, support preclinical and clinical research activities by our partners and develop these product candidates through to potential approval, We are developing a CAR T therapy for solid tumors in partnership with COH targeting IL13Rα2 (MB-101).

Financial trend for MUSTANG BIO, INC. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -$77.53 million (2022-12-31) to -$1.92 million (2025-12-31), a change of +97.5%; total assets went from $92.42 million (2022-12-31) to $17.59 million (2025-12-31), a change of -81.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1680048, tags Assets, NetIncomeLoss; 4 periods shown, dashes mark figures MUSTANG BIO, INC. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on MUSTANG BIO, INC. (CIK 1680048) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2024-04-29, and the most recent 10-K annual report was filed 2026-03-19. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 112 8-K or 6-K reports in MUSTANG BIO, INC.’s recent EDGAR index, the 4 listed here run from 2025-07-09 to 2026-10-15, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1680048 is on the EDGAR company page; the latest 10-K there is dated 2026-03-19 and the oldest filing in the recent index dates from 2016-07-28. Insider trades for MUSTANG BIO, INC. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Myriad uranium corp. bullish and bearish analyst opinions

For “Myriad uranium corp. bullish and bearish analyst opinions”, the matching SEC registrant is Myriad Uranium Corp., which trades as none listed and files under Central Index Key 1979836. EDGAR puts it in the “no SIC description” industry code with British Columbia, Canada as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a D filed 2025-10-01, across 8 filings on record. This is reference material, not trading advice.

Analyst ratings, price targets and “bullish” or “bearish” calls on Myriad Uranium Corp. (CIK 1979836) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

What kind of filer this is matters for “Myriad uranium corp. bullish and bearish analyst opinions”: Myriad Uranium Corp.’s EDGAR record from 2023-06-02 to 2025-10-01 consists only of Form D notices of exempt private offerings, which means it raised money privately rather than registering shares for public trading. It has no 10-K, 10-Q or 20-F, so the SEC holds no audited financial statements or annual business description for it; as a company organised in British Columbia, Canada, its own reports would be with the Canadian Securities Administrators’ SEDAR+ system (www.sedarplus.ca).

Other filings. Across its 8 recent EDGAR filings, Myriad Uranium Corp. most often filed D (8). A selection from 2024-08-26 to 2025-10-01:

The full record for CIK 1979836 is on the EDGAR company page and the oldest filing in the recent index dates from 2023-06-02. Insider trades for Myriad Uranium Corp. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Nanobiotix s.a. bullish and bearish analyst opinions

For “Nanobiotix s.a. bullish and bearish analyst opinions”, the matching SEC registrant is Nanobiotix S.A., which trades as NBTX, NNBXF and files under Central Index Key 1760854. EDGAR puts it in the “Pharmaceutical Preparations” industry code with France as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 6-K filed 2026-10-20, across 310 filings on record. This is reference material, not trading advice.

Business description, quoted from the 20-F filed 2026-03-31 by Nanobiotix S.A. (CIK 1760854) — source document:

We are registered at the Paris Registre du Commerce et des Sociétés under the number 447 521 600. Our principal executive offices are located at 60, rue de Wattignies, 75012 Paris, France, and our telephone number is +33 1 40 26 04 70. Our agent for service of process in the United States is our U.S. subsidiary, Nanobiotix Corporation, located at 245 Main Street, Cambridge, Massachusetts 02142. Our ordinary shares began trading on the regulated market of Euronext in Paris in October 2012. Our ADSs began trading on the Nasdaq Global Select Market on December 11, 2020. We were founded as a spin-off from the State University of New York, Buffalo in 2003.

Financial trend for Nanobiotix S.A. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from 4,776,000 EUR (2022-12-31) to 32,593,000 EUR (2025-12-31), a change of +582.4%; net income (loss) went from -57,000,000 EUR (2022-12-31) to -23,961,000 EUR (2025-12-31), a change of +58.0%; total assets went from 59,769,000 EUR (2022-12-31) to 67,760,000 EUR (2025-12-31), a change of +13.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1760854, tags Assets, ProfitLoss, Revenue; 4 periods shown, dashes mark figures Nanobiotix S.A. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Nanobiotix S.A. (CIK 1760854) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-03-31. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 232 8-K or 6-K reports in Nanobiotix S.A.’s recent EDGAR index, the 4 listed here run from 2026-09-24 to 2026-10-20, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1760854 is on the EDGAR company page; the latest 20-F there is dated 2026-03-31 and the oldest filing in the recent index dates from 2018-12-21. Insider trades for Nanobiotix S.A. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

National healthcare properties, inc. (nhp) bullish and bearish analyst opinions

For “National healthcare properties, inc. (nhp) bullish and bearish analyst opinions”, the matching SEC registrant is National Healthcare Properties, Inc., which trades as NHP, HLTC and files under Central Index Key 1561032. EDGAR puts it in the “Real Estate Investment Trusts” industry code with MD as its state or country of incorporation; its earlier registered name was Healthcare Trust, Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-22, across 564 filings on record. This is reference material, not trading advice.

Analyst ratings, price targets and “bullish” or “bearish” calls on National Healthcare Properties, Inc. (CIK 1561032) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-05, and the most recent 10-K annual report was filed 2026-02-20. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Updated Oct 25, 2026 ET

Neogen properties pvt ltd mobile apps

Because this search is about mobile apps from Neogen properties pvt ltd, the record that answers it is the developer listing in the app stores. Check Google Play (Developer field) and the App Store (Seller field): a match to the company’s legal name, plus a privacy policy hosted on its own domain, is what confirms an app is genuinely the company’s.

No SEC filer could be matched to “Neogen properties pvt ltd mobile apps” with a single, clear Central Index Key: neither EDGAR’s company index nor its full-text search (phrase “Neogen properties pvt ltd”) returns a registrant with this name. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “neogen” (search terms considered: neogen, properties, pvt).

Even the shorter phrase “Neogen properties pvt” returns no EDGAR full-text hits, so no SEC filing since 2001 mentions it; the terms in this search (neogen, properties, pvt) point to a business outside the SEC system or one known by another legal name.

The wording suggests a business based in India. Companies there file with NSE/BSE and the Securities and Exchange Board of India (SEBI) rather than with the U.S. SEC, unless they also list shares or ADRs in the United States. The primary disclosure route for “neogen” is therefore the India regulator or exchange site, where annual reports and stock-exchange announcements are published.

EDGAR’s company index has 2 entities whose registered name contains the word “neogen”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “neogen” 2, “properties” 482, “pvt” 14. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

Updated Oct 25, 2026 ET

New sparkle roll international group limited bullish and bearish analyst opinions

“Limited” is the company form used across Hong Kong, Australia, Singapore and other Commonwealth markets. The name “New sparkle roll international group limited” therefore points to a company organised in a Commonwealth jurisdiction (most often Hong Kong, Australia, Singapore or Canada), and its official disclosures are on that market’s exchange filing system (HKEXnews, ASX announcements, SGXNet or SEDAR+) (www.hkexnews.hk), not on EDGAR.

No SEC filer could be matched to “New sparkle roll international group limited bullish and bearish analyst opinions” with a single, clear Central Index Key: the phrase “New sparkle roll international group limited” appears in 29 EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “sparkle” (search terms considered: sparkle, roll, international).

A broader EDGAR full-text search for the shorter phrase “sparkle roll international” finds 329+ filing documents; among the top 100, the filers mentioning it most are DFA INVESTMENT DIMENSIONS GROUP INC (CIK 0000355437) (51); DFA INVESTMENT TRUST CO (CIK 0000896162) (28); AMERICAN CENTURY ETF TRUST (CIK 0001710607) (17). Those are documents that name the term, not proof that any of these filers is the business in the search.

In the 29 most relevant full-text hits returned for “New sparkle roll international group limited”, filings range from 2021-12-29 to 2026-07-23. The filers whose documents mention it most often are OneConstruction Group Ltd (ONEG) (CIK 0002030834) (11 hits); Dimensional ETF Trust (CIK 0001816125) (11 hits); OneConstruction Group Ltd (CIK 0002030834) (4 hits); AMERICAN CENTURY ETF TRUST (CIK 0001710607) (2 hits). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

EDGAR’s company index has 8 entities whose registered name contains the word “sparkle”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “sparkle” 8, “roll” 500+, “international” 458. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: analyst views on “sparkle” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Nkarta, inc. bullish and bearish analyst opinions

For “Nkarta, inc. bullish and bearish analyst opinions”, the matching SEC registrant is Nkarta, Inc., which trades as NKTX and files under Central Index Key 1787400. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 10-Q filed 2026-08-10, across 436 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-25 by Nkarta, Inc. (CIK 1787400) — source document:

We are a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer ("NK") cell therapies. Our company was founded on the belief that engineered NK cell therapies can transform the lives of patients by offering therapies that are clinically meaningful, broadly accessible and unencumbered by the safety concerns often associated with other cell therapy approaches. Our lead pipeline program is NKX019, a chimeric antigen receptor-natural killer ("CAR NK") product candidate targeting the CD19 antigen for the treatment of patients with autoimmune diseases. Our CAR NK platform enables an on-demand, off-the-shelf approach involving scaled manufacturing to broaden patient access. We have developed proprietary technologies designed to generate an abundant supply of NK cells, increase NK cell recognition of target antigens, and enhance NK cell fitness to support scalable, off the shelf administration.

Financial trend for Nkarta, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $0 (2024-12-31) to $0 (2025-12-31); net income (loss) went from -$113.84 million (2022-12-31) to -$104.08 million (2025-12-31), a change of +8.6%; total assets went from $472.94 million (2022-12-31) to $404.21 million (2025-12-31), a change of -14.5%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1787400, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures Nkarta, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Nkarta, Inc. (CIK 1787400) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-10, and the most recent 10-K annual report was filed 2026-03-25. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 60 8-K or 6-K reports in Nkarta, Inc.’s recent EDGAR index, the 4 listed here run from 2026-03-26 to 2026-08-10, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1787400 is on the EDGAR company page; the latest 10-K there is dated 2026-03-25 and the oldest filing in the recent index dates from 2019-09-06. Insider trades for Nkarta, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Oak view bankshares, inc. bullish and bearish analyst opinions

For “Oak view bankshares, inc. bullish and bearish analyst opinions”, the matching SEC registrant is Oak View Bankshares, Inc., which trades as OAKV and files under Central Index Key 1865429. EDGAR puts it in the “National Commercial Banks” industry code with VA as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a D filed 2025-10-24, across 10 filings on record. This is reference material, not trading advice.

Analyst ratings, price targets and “bullish” or “bearish” calls on Oak View Bankshares, Inc. (CIK 1865429) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

What kind of filer this is matters for “Oak view bankshares, inc. bullish and bearish analyst opinions”: Oak View Bankshares, Inc.’s EDGAR record from 2021-06-09 to 2025-10-24 consists only of 1-A filings; 1-K filings; 1-SA filings; 1-Z filings; CORRESP filings; Form D notices of exempt private offerings, which means it raised money privately rather than registering shares for public trading; QUALIF filings; UPLOAD filings. It has no 10-K, 10-Q or 20-F, so the SEC holds no audited financial statements or annual business description for it.

Other filings. Across its 10 recent EDGAR filings, Oak View Bankshares, Inc. most often filed D (3), 1-Z (1), 1-K (1), 1-SA (1). A selection from 2022-03-03 to 2025-10-24:

The full record for CIK 1865429 is on the EDGAR company page and the oldest filing in the recent index dates from 2021-06-09. Insider trades for Oak View Bankshares, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Opus magnum ameris, inc. bullish and bearish analyst opinions

What this search refers to. “Opus Magnum Ameris, Inc.” has no EDGAR record; a corporation of that name, if it exists, would be found in the business registry of its state of incorporation. Corporate-registry check: OpenCorporates search for “Opus magnum ameris, inc.”.

No SEC filer could be matched to “Opus magnum ameris, inc. bullish and bearish analyst opinions” with a single, clear Central Index Key: the phrase “Opus magnum ameris, inc.” appears in 23 EDGAR full-text search results, but those hits do not point to one clearly identifiable issuer with its own CIK. Rather than show another company’s numbers, this section explains what the official record does and does not contain for the term “opus” (search terms considered: opus, magnum, ameris).

A broader EDGAR full-text search for the shorter phrase “Opus magnum ameris” finds 23 filing documents; among the top 23, the filers mentioning it most are NVWM, LLC (CIK 0001697274) (23). Those are documents that name the term, not proof that any of these filers is the business in the search.

In the 23 most relevant full-text hits returned for “Opus magnum ameris, inc.”, filings range from 2018-03-15 to 2023-08-08. The filers whose documents mention it most often are NVWM, LLC (CIK 0001697274) (23 hits). A mention in another company’s filing — as a customer, supplier, lender, fund holding or deal counterparty — does not make that filer the company you searched for.

EDGAR’s company index has 102 entities whose registered name contains the word “opus”; the first few are shown below so you can see whether any is the business you mean. None of them matches the full search wording closely enough to be treated as the same company.

Word by word, the number of EDGAR registrant names containing each term of this search is: “opus” 102, “magnum” 66, “ameris” 2. A term that appears in many unrelated names is a weak identifier on its own, which is why this page does not attach any one filer’s financial data to the query.

For this particular search: analyst views on “opus” are third-party opinions; the SEC neither issues nor reviews ratings, so check any rating against the company’s own annual report. If the business says it is registered but does not appear in EDGAR or on FINRA BrokerCheck, treat that as a red flag. This page offers no buy or sell recommendation.

Updated Oct 25, 2026 ET

Oramed pharmaceuticals inc. bullish and bearish analyst opinions

For “Oramed pharmaceuticals inc. bullish and bearish analyst opinions”, the matching SEC registrant is ORAMED PHARMACEUTICALS INC., which trades as ORMP and files under Central Index Key 1176309. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation; its earlier registered name was Integrated Security Technologies, Inc. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-02, across 941 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-26 by ORAMED PHARMACEUTICALS INC. (CIK 1176309) — source document:

In addition, we allocate capital to strategic investments in healthcare and life sciences companies that we believe complement our long-term business objectives and technology focus. We have developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. The formulation is not intended to modify the proteins chemically or biologically, and the dosage form is designed to be safe to ingest. We intend to initiate, in the second half of 2026, a 60-patient, US-based clinical trial designed to validate the robustness of our oral insulin formulation in defined patient population. The trial is designed to use the smallest adequately powered patient population expected to obtain such validation in what we believe to be the shortest time possible, providing a cost-effective approach to generate additional compelling evidence and refine our patient selection criteria for future potential regulatory submissions.

Financial trend for ORAMED PHARMACEUTICALS INC. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $2.70 million (2022-12-31) to $2.00 million (2025-12-31), a change of -26.0%; net income (loss) went from -$36.56 million (2022-12-31) to $64.05 million (2025-12-31), a change of +275.2%; total assets went from $161.64 million (2022-12-31) to $230.86 million (2025-12-31), a change of +42.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1176309, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures ORAMED PHARMACEUTICALS INC. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on ORAMED PHARMACEUTICALS INC. (CIK 1176309) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2025-11-17, and the most recent 10-K annual report was filed 2026-03-26. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 264 8-K or 6-K reports in ORAMED PHARMACEUTICALS INC.’s recent EDGAR index, the 4 listed here run from 2026-02-20 to 2026-09-17, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1176309 is on the EDGAR company page; the latest 10-K there is dated 2026-03-26 and the oldest filing in the recent index dates from 2002-11-29. Insider trades for ORAMED PHARMACEUTICALS INC. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Orchestra biomed holdings, inc. bullish and bearish analyst opinions

For “Orchestra biomed holdings, inc. bullish and bearish analyst opinions”, the matching SEC registrant is Orchestra BioMed Holdings, Inc., which trades as OBIO and files under Central Index Key 1814114. EDGAR puts it in the “Surgical & Medical Instruments & Apparatus” industry code with DE as its state or country of incorporation; its earlier registered name was Health Sciences Acquisitions Corp 2. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-02, across 409 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-12 by Orchestra BioMed Holdings, Inc. (CIK 1814114) — source document:

Our Vision Our vision is to accelerate medical innovation to patients through risk-reward-sharing partnerships with leading medical device companies. Our Company We are a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. We are led by a highly accomplished, multidisciplinary management team and a board of directors with extensive experience in all phases of therapeutic device development. Our business was formed in 2018 by assembling a pipeline of multiple late-stage clinical product candidates originally developed by our founding team. Our flagship product candidates are Atrioventricular Interval Modulation Therapy (“AVIM Therapy”) for the treatment of hypertension (“HTN”), the leading risk factor for death worldwide, and Virtue® Sirolimus AngioInfusion™ Balloon (“Virtue SAB”) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide.

Financial trend for Orchestra BioMed Holdings, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $3.53 million (2022-12-31) to $33.48 million (2025-12-31), a change of +847.7%; net income (loss) went from -$33.61 million (2022-12-31) to -$52.70 million (2025-12-31), a change of -56.8%; total assets went from $95.57 million (2022-12-31) to $114.86 million (2025-12-31), a change of +20.2%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1814114, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures Orchestra BioMed Holdings, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Orchestra BioMed Holdings, Inc. (CIK 1814114) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 10-K annual report was filed 2026-03-12. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 43 8-K or 6-K reports in Orchestra BioMed Holdings, Inc.’s recent EDGAR index, the 4 listed here run from 2026-02-13 to 2026-10-01, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1814114 is on the EDGAR company page; the latest 10-K there is dated 2026-03-12 and the oldest filing in the recent index dates from 2020-06-22. Insider trades for Orchestra BioMed Holdings, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Orthofix medical inc. bullish and bearish analyst opinions

For “Orthofix medical inc. bullish and bearish analyst opinions”, the matching SEC registrant is Orthofix Medical Inc., which trades as OFIX and files under Central Index Key 884624. EDGAR puts it in the “Surgical & Medical Instruments & Apparatus” industry code with an unstated jurisdiction as its state or country of incorporation; its earlier registered name was ORTHOFIX INTERNATIONAL N V. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-05, across 1006 filings on record. This is reference material, not trading advice.

Financial trend for Orthofix Medical Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $460.71 million (2022-12-31) to $822.31 million (2025-12-31), a change of +78.5%; net income (loss) went from -$19.75 million (2022-12-31) to -$92.19 million (2025-12-31), a change of -366.8%; total assets went from $458.63 million (2022-12-31) to $850.65 million (2025-12-31), a change of +85.5%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 884624, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures Orthofix Medical Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Orthofix Medical Inc. (CIK 884624) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-05, and the most recent 10-K annual report was filed 2026-02-24. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 183 8-K or 6-K reports in Orthofix Medical Inc.’s recent EDGAR index, the 4 listed here run from 2026-05-21 to 2026-08-05, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 1006 recent EDGAR filings, Orthofix Medical Inc. most often filed 4 (461), 8-K (183), 3 (51), SC 13G/A (46). A selection from 2026-09-01 to 2026-10-05:

The full record for CIK 884624 is on the EDGAR company page; the latest 10-K there is dated 2026-02-24 and the oldest filing in the recent index dates from 2012-08-01. Insider trades for Orthofix Medical Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Pacific empire minerals corp. bullish and bearish analyst opinions

For “Pacific empire minerals corp. bullish and bearish analyst opinions”, the matching SEC registrant is Pacific Empire Minerals Corp, which trades as none listed and files under Central Index Key 1575193. EDGAR puts it in the “no SIC description” industry code with British Columbia, Canada as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a D/A filed 2018-05-01, across 6 filings on record. This is reference material, not trading advice.

Analyst ratings, price targets and “bullish” or “bearish” calls on Pacific Empire Minerals Corp (CIK 1575193) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

What kind of filer this is matters for “Pacific empire minerals corp. bullish and bearish analyst opinions”: Pacific Empire Minerals Corp’s EDGAR record from 2013-04-25 to 2018-05-01 consists only of D/A filings; Form D notices of exempt private offerings, which means it raised money privately rather than registering shares for public trading. It has no 10-K, 10-Q or 20-F, so the SEC holds no audited financial statements or annual business description for it; as a company organised in British Columbia, Canada, its own reports would be with the Canadian Securities Administrators’ SEDAR+ system (www.sedarplus.ca).

Other filings. Across its 6 recent EDGAR filings, Pacific Empire Minerals Corp most often filed D (5), D/A (1). A selection from 2016-06-14 to 2018-05-01:

The full record for CIK 1575193 is on the EDGAR company page and the oldest filing in the recent index dates from 2013-04-25. Insider trades for Pacific Empire Minerals Corp appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Pan american silver stock

For “Pan american silver stock”, the matching SEC registrant is PAN AMERICAN SILVER CORP, which trades as PAAS, PAASF and files under Central Index Key 771992. EDGAR puts it in the “Gold and Silver Ores” industry code with an unstated jurisdiction as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 6-K filed 2026-10-07, across 911 filings on record. This is reference material, not trading advice.

Financial trend for PAN AMERICAN SILVER CORP from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $1.49 billion (2022-12-31) to $3.62 billion (2025-12-31), a change of +142.1%; net income (loss) went from -$340.10 million (2022-12-31) to $980.00 million (2025-12-31), a change of +388.2%; total assets went from $3.25 billion (2022-12-31) to $9.74 billion (2025-12-31), a change of +199.9%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 771992, tags Assets, ProfitLoss, Revenue; 4 periods shown, dashes mark figures PAN AMERICAN SILVER CORP did not tag for that period.

PAN AMERICAN SILVER CORP has 911 filings in its recent EDGAR index, including 25 annual reports and 0 quarterly reports; its newest filing is a 6-K from 2026-10-07.

Current reports. Of the 708 8-K or 6-K reports in PAN AMERICAN SILVER CORP’s recent EDGAR index, the 4 listed here run from 2026-08-13 to 2026-10-07, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 911 recent EDGAR filings, PAN AMERICAN SILVER CORP most often filed 6-K (708), SC 13G/A (47), 40-F (25), SC 13G (14). A selection from 2025-10-17 to 2026-07-09:

The full record for CIK 771992 is on the EDGAR company page; the latest 40-F there is dated 2026-02-18 and the oldest filing in the recent index dates from 1998-02-11. Insider trades for PAN AMERICAN SILVER CORP appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Pepgen inc. bullish and bearish analyst opinions

For “Pepgen inc. bullish and bearish analyst opinions”, the matching SEC registrant is PepGen Inc., which trades as PEPG and files under Central Index Key 1835597. EDGAR puts it in the “Pharmaceutical Preparations” industry code with DE as its state or country of incorporation. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-08-06, across 304 filings on record. This is reference material, not trading advice.

Financial trend for PepGen Inc. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -$69.10 million (2022-12-31) to -$89.66 million (2025-12-31), a change of -29.7%; total assets went from $217.44 million (2022-12-31) to $173.91 million (2025-12-31), a change of -20.0%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1835597, tags Assets, NetIncomeLoss; 4 periods shown, dashes mark figures PepGen Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on PepGen Inc. (CIK 1835597) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-06, and the most recent 10-K annual report was filed 2026-03-04. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 65 8-K or 6-K reports in PepGen Inc.’s recent EDGAR index, the 4 listed here run from 2026-05-12 to 2026-08-06, with the item codes the company selected and what each code covers under SEC rules.

Other filings. Across its 304 recent EDGAR filings, PepGen Inc. most often filed 4 (98), 8-K (65), 3 (21), 10-Q (14). A selection from 2026-06-22 to 2026-08-06:

The full record for CIK 1835597 is on the EDGAR company page; the latest 10-K there is dated 2026-03-04 and the oldest filing in the recent index dates from 2020-12-09. Insider trades for PepGen Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Pharvaris n.v. bullish and bearish analyst opinions

For “Pharvaris n.v. bullish and bearish analyst opinions”, the matching SEC registrant is Pharvaris N.V., which trades as PHVS and files under Central Index Key 1830487. EDGAR puts it in the “Pharmaceutical Preparations” industry code with Netherlands as its state or country of incorporation; its earlier registered name was Pharvaris, B.V.. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-10-13, across 327 filings on record. This is reference material, not trading advice.

Business description, quoted from the 20-F filed 2026-04-02 by Pharvaris N.V. (CIK 1830487) — source document:

OPERATING AND FINANCIAL REVIEW AND PROSPECTS 78 A. Operating results 78 B. Liquidity and capital resources 84 C. Research and development, patents and licenses, etc. 86 D. Trend information 86 E. Critical accounting estimates 87 ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES 88 A. Directors and senior management 88 B. Compensation 91 C. Board practices 97 D. Employees 99 E. Share ownership 99 F. Disclosure of a registrant’s action to recover erroneously awarded compensation 99 ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS 100 A. Major shareholders 100 B. Related party transactions 102 C. Interests of Experts and Counsel 104 ITEM 8. FINANCIAL INFORMATION 104 A. Consolidated statements and other financial information 104 B. Significant changes 105 ITEM 9.

Financial trend for Pharvaris N.V. from annual reports, periods 2022-12-31 to 2025-12-31: net income (loss) went from -76,332,557 EUR (2022-12-31) to -175,699,397 EUR (2025-12-31), a change of -130.2%; total assets went from 167,732,983 EUR (2022-12-31) to 301,454,999 EUR (2025-12-31), a change of +79.7%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1830487, tags Assets, ProfitLoss; 4 periods shown, dashes mark figures Pharvaris N.V. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on Pharvaris N.V. (CIK 1830487) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on, and the most recent 20-F annual report was filed 2026-04-02. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 73 8-K or 6-K reports in Pharvaris N.V.’s recent EDGAR index, the 4 listed here run from 2026-06-26 to 2026-09-08, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1830487 is on the EDGAR company page; the latest 20-F there is dated 2026-04-02 and the oldest filing in the recent index dates from 2020-11-12. Insider trades for Pharvaris N.V. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Phenixfin corporation bullish and bearish analyst opinions

For “Phenixfin corporation bullish and bearish analyst opinions”, the matching SEC registrant is PhenixFIN Corp, which trades as PFX, PFXNZ and files under Central Index Key 1490349. EDGAR puts it in the “no SIC description” industry code with DE as its state or country of incorporation; its earlier registered name was Medley Capital Corp. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 10-Q filed 2026-08-05, across 891 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2025-12-12 by PhenixFIN Corp (CIK 1490349) — source document:

PhenixFIN Corporation (“PhenixFIN”, the “Company,” “we” and “us”) is an internally-managed non-diversified closed-end management investment company incorporated in Delaware that has elected to be regulated as a business development company (“BDC”) under the Investment Company Act of 1940, as amended (the “1940 Act”). We completed our initial public offering (“IPO”) and commenced operations on January 20, 2011. The Company has elected, and intends to qualify annually, to be treated, for U.S. federal income tax purposes, as a regulated investment company (“RIC”) under Subchapter M of the Internal Revenue Code of 1986, as amended (the “Code”). Through December 31, 2020, we were an externally managed company. Since January 1, 2021, we have operated under our present internalized management structure.

Financial trend for PhenixFIN Corp from annual reports, periods 2022-09-30 to 2025-09-30: net income (loss) went from -$6.11 million (2022-09-30) to $4.16 million (2025-09-30), a change of +168.0%; total assets went from $218.87 million (2022-09-30) to $316.91 million (2025-09-30), a change of +44.8%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1490349, tags Assets, NetIncomeLoss; 4 periods shown, dashes mark figures PhenixFIN Corp did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on PhenixFIN Corp (CIK 1490349) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-05, and the most recent 10-K annual report was filed 2025-12-12. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 162 8-K or 6-K reports in PhenixFIN Corp’s recent EDGAR index, the 4 listed here run from 2026-02-09 to 2026-08-05, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1490349 is on the EDGAR company page; the latest 10-K there is dated 2025-12-12 and the oldest filing in the recent index dates from 2010-05-03. Insider trades for PhenixFIN Corp appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Pixelworks, inc. bullish and bearish analyst opinions

For “Pixelworks, inc. bullish and bearish analyst opinions”, the matching SEC registrant is PIXELWORKS, INC, which trades as PXLW and files under Central Index Key 1040161. EDGAR puts it in the “Services-Prepackaged Software” industry code with OR as its state or country of incorporation; its earlier registered name was PIXELWORKS INC. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 4 filed 2026-08-20, across 1000 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-12 by PIXELWORKS, INC (CIK 1040161) — source document:

Pixelworks, Inc. (the “Company” or “Pixelworks”) provides industry-leading content creation, video delivery and display processing solutions, and technology that enable highly authentic viewing experiences with superior visual quality across all screens, from cinema to smartphone and beyond. Pixelworks has been delivering image processing innovations to leading providers of consumer electronics, professional displays, and video streaming services for more than 20 years. On January 6, 2026 (the “Closing Date”), the Company completed the previously announced sale (the “Sale”) of all of the shares of common stock of Pixelworks Semiconductor Technology (Shanghai) Co., Ltd. (“PWSH”) held by Pixelworks Semiconductor Technology Company, LLC, a wholly owned subsidiary of the Company (“Pixelworks LLC”), to Tiansui Xinyuan Technology (Shanghai) Co., Ltd. (the “Buyer”).

Financial trend for PIXELWORKS, INC from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $70.15 million (2022-12-31) to $693,000 (2025-12-31), a change of -99.0%; net income (loss) went from -$16.03 million (2022-12-31) to -$22.50 million (2025-12-31), a change of -40.4%; total assets went from $102.32 million (2022-12-31) to $51.26 million (2025-12-31), a change of -49.9%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1040161, tags Assets, NetIncomeLoss, Revenues; 4 periods shown, dashes mark figures PIXELWORKS, INC did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on PIXELWORKS, INC (CIK 1040161) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-11, and the most recent 10-K annual report was filed 2026-03-12. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 216 8-K or 6-K reports in PIXELWORKS, INC’s recent EDGAR index, the 4 listed here run from 2026-03-31 to 2026-08-11, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1040161 is on the EDGAR company page; the latest 10-K there is dated 2026-03-12 and the oldest filing in the recent index dates from 2007-04-20. Insider trades for PIXELWORKS, INC appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET

Playstudios, inc. bullish and bearish analyst opinions

For “Playstudios, inc. bullish and bearish analyst opinions”, the matching SEC registrant is PLAYSTUDIOS, Inc., which trades as MYPS and files under Central Index Key 1823878. EDGAR puts it in the “Services-Prepackaged Software” industry code with an unstated jurisdiction as its state or country of incorporation; its earlier registered name was Acies Acquisition Corp. Data below comes straight from EDGAR as checked on Oct 25, 2026, where the latest item is a 8-K filed 2026-10-19, across 381 filings on record. This is reference material, not trading advice.

Business description, quoted from the 10-K filed 2026-03-16 by PLAYSTUDIOS, Inc. (CIK 1823878) — source document:

Acies was incorporated on August 14, 2020 for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. Acies completed its initial public offering in October 2020. On June 21, 2021, Acies consummated the Acies Merger with Old PLAYSTUDIOS, pursuant to the Merger Agreement. In connection with the closing of the Acies Merger , we changed our name to PLAYSTUDIOS, Inc. PLAYSTUDIOS continues the existing business operations of Old PLAYSTUDIOS as a publicly traded company. Our website address is www.playstudios.com . Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act are made available free of charge on our website as soon as reasonably practicable after we have electronically filed the material with, or furnished it to, the SEC. Overview PLAYSTUDIOS is a developer of free-to-play casual games for mobile and social platforms.

Financial trend for PLAYSTUDIOS, Inc. from annual reports, periods 2022-12-31 to 2025-12-31: revenue went from $290.31 million (2022-12-31) to $235.10 million (2025-12-31), a change of -19.0%; net income (loss) went from -$17.78 million (2022-12-31) to -$28.64 million (2025-12-31), a change of -61.0%; total assets went from $352.01 million (2022-12-31) to $290.62 million (2025-12-31), a change of -17.4%. Values are as filed and not adjusted for restatements, splits or currency.

Data: SEC XBRL company facts for CIK 1823878, tags Assets, NetIncomeLoss, RevenueFromContractWithCustomerExcludingAssessedTax; 4 periods shown, dashes mark figures PLAYSTUDIOS, Inc. did not tag for that period.

Analyst ratings, price targets and “bullish” or “bearish” calls on PLAYSTUDIOS, Inc. (CIK 1823878) are third-party opinions that the SEC does not publish or check. What the regulator does hold are the facts those views are built on: the latest results release filed under 8-K Item 2.02 is dated 2026-08-11, and the most recent 10-K annual report was filed 2026-03-16. Comparing any rating with those primary documents shows whether the thesis matches what the company itself reported.

Current reports. Of the 61 8-K or 6-K reports in PLAYSTUDIOS, Inc.’s recent EDGAR index, the 4 listed here run from 2026-09-25 to 2026-10-19, with the item codes the company selected and what each code covers under SEC rules.

The full record for CIK 1823878 is on the EDGAR company page; the latest 10-K/A there is dated 2026-04-03 and the oldest filing in the recent index dates from 2020-09-22. Insider trades for PLAYSTUDIOS, Inc. appear as Forms 3, 4 and 5, and holders above 5% file Schedules 13D or 13G.

Updated Oct 25, 2026 ET